Registration Cancellation Risks under Article 376 of Mexico Health Law

1. Key takeaways

Following the amendment decree of DOF 2026-01-15, Article 376 of the LGS sets out the circumstances in which a health registration may be cancelled, including failure to apply for renewal within the prescribed period, making unauthorised changes to the device, and changing the raw material manufacturer without prior approval. Once a registration is cancelled, the manufacture, marketing and distribution of the product in Mexico lose their legal basis. None of the listed grounds involves a technical failure of the device; all three are administrative acts that a functioning compliance calendar would have prevented. That is the practical core of this topic: cancellation risk in Mexico is managed not in the laboratory but in the registry of deadlines, change gates and supplier approvals. Every element of that registry is within the company’s own control, which is both the warning and the reassurance.

• Cancellation is a formal administrative procedure, not an automatic lapse, so the company has the opportunity to present evidence and remediate within the procedure.
• The three high-risk grounds are late renewal, unauthorised device changes and unapproved changes of raw material manufacturer.
• The consequences are immediate: without a valid registration, production, marketing and distribution lose their legal basis and import permits cannot be applied for.
• Repeated failures against the vigilance reporting deadlines of NOM-240-SSA1-2012 sections 12.3.1–12.3.3 accelerate regulatory intervention.
• The same 2026 amendment extended subsequent renewals to 10 years, reducing renewal frequency and structurally lowering the risk of cancellation for late renewal.

2. Legal basis

The cancellation regime is defined by the amended General Health Law provision, implemented through the renewal deadlines of the RIS, underpinned by the registration requirement of Article 82, and shadowed by the vigilance duties of NOM-240-SSA1-2012. The four sources are set out below.

3. Expert insights

Insight one: cancellation is an administrative procedure, not an automatic lapse. Article 376 treats cancellation as a formal administrative procedure. This carries procedural requirements, and it also means the company has the opportunity to present evidence and take corrective action within the procedure. The distinction matters in practice: a company with an organised compliance file can respond to a cancellation process far more effectively than one reconstructing records under deadline pressure, and the procedural character of the process is what preserves that chance.

Insight two: all three high-risk grounds are management failures, not technical ones. Missing a renewal deadline, changing the device without authorisation, switching the raw material manufacturer without approval — none of these is a difficult engineering problem. They are process management failures, and they are prevented by ledgers and approval gates. Companies that maintain a registration ledger, a change control gate and a supplier approval workflow hold all three risks in check as a by-product of ordinary governance.

Insight three: the consequences of cancellation are immediate. Without a valid registration, the manufacture, marketing and distribution of the product no longer have a legal basis, and import permits cannot be applied for. This is not a minor violation settled with a fine. The market position itself is lost, and rebuilding it requires a new registration rather than a reinstatement of the old one, which is what makes prevention so disproportionately valuable. The cost of the ledger and the calendar is trivial; the cost of losing the market position is not measured in fees at all.

Insight four: vigilance failures compound the risk. If reporting deadlines are repeatedly missed under sections 12.3.1–12.3.3 of NOM-240-SSA1-2012, regulatory intervention accelerates. Vigilance timeliness should be included in the performance metrics of the registration holder, so that the party responsible for reporting is measured on it. A pattern of late reports turns a routine relationship with the authority into a scrutinised one, and that scrutiny spreads to everything else the holder files.

Insight five: the 2026 amendment also lengthened the renewal cycle. Alongside the cancellation risk, Article 376 extended the validity of subsequent renewals to 10 years, reducing the frequency of renewals and structurally lowering the probability of cancellation for late filing. The two effects move in opposite directions on the risk register: less frequent renewals mean fewer occasions on which a deadline can be missed, provided the ledger that tracks the longer interval is adjusted accordingly.

4. Practical recommendations

• Maintain a registration ledger with three mandatory fields: validity period, renewal reminder (18 months before expiry) and amendment approval status.
• Route any change to design, process, materials or suppliers through the amendment assessment first; do not change the marketed state of the product without approval.
• Treat a change of raw material manufacturer as a separate high-risk action requiring prior approval before implementation.
• Include vigilance reporting timeliness in the holder’s KPIs, with internal lead times set against the 2 business days / 10 days / 30 days reporting tiers.
• On receipt of notice of a cancellation procedure, assemble the supporting evidence immediately and respond within the procedural deadlines.

5. Verification checklist

• □ The registration ledger includes the validity period and renewal reminder (18 months before expiry)
• □ Changes to design / process / materials / suppliers pass the amendment assessment
• □ Changes of raw material manufacturer require prior approval
• □ Vigilance timeliness is included in the holder’s KPIs
• □ A response plan for cancellation procedures is prepared

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com